Mycophenolatmofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolatmofetil Accord, is an immunosuppressant (antimetabolite) presented as an intravenous formulation for use in transplant and autoimmune disease management. It works by inhibiting lymphocyte proliferation, helping to prevent organ rejection and control severe autoimmune activity.

GNH USA supplies Mycophenolatmofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is employed in conditions where immune suppression is required, particularly in transplant and autoimmune pathways.

- Organ transplant rejection: helps prevent acute and chronic rejection by suppressing T‑cell activation. - Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus. - Other autoimmune diseases (e.g., vasculitis): controls disease activity by limiting lymphocyte proliferation.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools, sometimes leading to dehydration. - Headache: transient cranial discomfort. - Hypertension: elevated blood pressure readings. - Infections: increased susceptibility to bacterial, viral, or fungal infections. - Anemia: reduced red blood cell count causing fatigue.

Serious or Rare Side Effects: - Leukopenia: marked decrease in white blood cells, raising infection risk. - Severe infection: opportunistic infections such as CMV or PCP. - Malignancy: increased long‑term risk of lymphoproliferative disorders. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Gastrointestinal perforation: rare but life‑threatening bowel injury.

Mycophenolate Mofetil requires careful monitoring and patient education.

- Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess renal function: adjust therapy if creatinine clearance declines. - Pregnancy safety: avoid use in pregnancy unless benefits outweigh risks; drug is category D. - Infection vigilance: screen for latent infections and treat promptly. - Hepatic monitoring: check liver enzymes periodically. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mycophenolate Mofetil can interact with several agents, altering efficacy or safety.

Major Interactions (Avoid): - Azathiidine: additive bone‑marrow suppression may cause severe cytopenias. - Live vaccines: increased risk of vaccine‑derived infection; avoid concurrent use. - Strong CYP3A4 inducers (e.g., rifampin): markedly reduce mycophenolate exposure.

Moderate Interactions (Monitor Closely): - Tacrolimus or cyclosporine: combined nephrotoxicity; monitor renal parameters. - Warfarin: potential alteration of INR; check coagulation status regularly. - ACE inhibitors or ARBs: may increase risk of hyperkalemia; monitor electrolytes.